Lansforsakringar Fondforvaltning’s United Therapeutics UTHR Stock Holding History

Lansforsakringar Fondforvaltning’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.44M	Sell	11,892 -1,504	-11%	-$847K	0.03%	400
2026 Q1	$7.94M	Buy	13,396 +39	+0.3%	+$19.4K	0.04%	318
2025 Q4	$6.51M	Buy	13,357 +174	+1%	+$81K	0.03%	359
2025 Q3	$5.53M	Buy	13,183 +29	+0.2%	+$9.75K	0.03%	382
2025 Q2	$3.78M	Sell	13,154 -387	-3%	-$116K	0.02%	438
2025 Q1	$4.17M	Hold	13,541	–	–	0.03%	421
2024 Q4	$4.78M	Buy	+13,541	New	+$4.98M	0.03%	408

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Lansforsakringar Fondforvaltning's UTHR Position: Q2 2026 in Review

Lansforsakringar Fondforvaltning reduced its United Therapeutics (UTHR) stake by 11% in Q2 2026, selling an estimated $847K and leaving 11,892 shares worth $6.44M. The position accounts for 0.03% of the portfolio, ranked #400.

Lansforsakringar Fondforvaltning first reported a position in UTHR in Q4 2024 and has held it in 7 quarters since. The position peaked at $7.94M in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Lansforsakringar Fondforvaltning held 11,892 shares of United Therapeutics worth $6.44M as of Q2 2026.
Lansforsakringar Fondforvaltning sold 1,504 United Therapeutics shares in Q2 2026, an estimated $847K.
United Therapeutics made up 0.03% of Lansforsakringar Fondforvaltning's portfolio in Q2 2026, its #400 holding.
Lansforsakringar Fondforvaltning first reported a position in United Therapeutics in Q4 2024 and has held it in 7 quarters since.
Lansforsakringar Fondforvaltning's United Therapeutics position peaked at $7.94M in Q1 2026.
884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Lansforsakringar Fondforvaltning's 13F filing for Q2 2026, filed 13 Aug 2026.